Annexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory ...
diginomica

Did we build the engine before we worked out the physics? What's the pathway to take after the LLM transformer?

Does AI have the cart before the horse? Zuzanna Stamirowska is CEO of Pathway, a company has just been valued at $500 million on the strength of a post-transformer architecture built on first ...

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, ...